Status:
RECRUITING
Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Lead Sponsor:
University Hospital Goettingen
Collaborating Sponsors:
Society for Pediatric Nephrology (Germany)
Conditions:
Alport Syndrome
Hereditary Kidney Disease
Eligibility:
All Genders
Brief Summary
The hereditary type IV collagen disease Alport syndrome leads to kidney failure early in life. Currently there are no specific medications approved for treatment, however, several therapies have been ...
Detailed Description
Early diagnosis in children with Alport syndrome (AS) with isolated hematuria opens a "window of opportunity" for early intervention. In the Alport mouse-model, this early intervention with the ACE-in...
Eligibility Criteria
Inclusion Criteria:
Diagnosis of Alport syndrome (AS) by kidney biopsy or mutation analysis (or both).
Any type of genetic variant is accepted for X-linked, autosomal or digenic Alport syndrome (COL4A3, 4 or 5 genes).
Exclusion criteria:
Patients not willing to give informed consent. Patient with suspected diagnosis, whcih cannot be confirmed.
Key Trial Info
Start Date :
July 1 1995
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2036
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT02378805
Start Date
July 1 1995
End Date
March 1 2036
Last Update
March 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Göttingen
Göttingen, Lower Saxony, Germany, 37075